Articles related to MIGRAINES/HEADACHES

Recent findings presented at the ASA’s annual meeting spotlight the critical role of tranexamic acid in postpartum hemorrhage, underscoring a dose-response relationship that enhances antifibrinolysis, marking a significant advancement in obstetric care.

The recent TikTok trend of using hot foot baths for migraine relief is an emerging trend in patient-led treatments. Although it may seem unconventional, there’s potential scientific backing related to the autonomic nervous system that warrants further exploration.

Gain insights into the new, evidence-based guidelines for managing postdural puncture headache, a condition that has long been in need of standardized care protocols.

Enhance your diagnostic acumen and patient management skills in the realm of ocular migraines with this comprehensive CE program.

Explore the findings of a retrospective study examining treatment persistence in migraine patients using CGRP mAb therapies or Botox – the results may surprise you.

FDA’s New Approval of Atogepant for Chronic Migraine Prevention is a Breakthrough in Migraine Management A promising breakthrough in migraine management, the FDA’s new approval of atogepant tablets, brings renewed hope for chronic migraine sufferers. According to AbbVie, this endorsement allows the use of atogepant (Qulipta) in the prevention of chronic migraines in adults. Atogepant stands out as the first oral calcitonin gene-related peptide (CGRP) receptor antagonist to receive dual approval for episodic and chronic migraines. It works by blocking CGRP, a molecule involved in transmitting pain signals. Chronic migraines, to clarify, involve enduring headaches for at least 15 days a month, with eight of those days associated with migraines. Before this, in September 2021, the FDA approved atogepant for treating episodic migraines. Patients can take the drug in 10 mg, 30 mg, and 60 mg dosages. The FDA recommends the 60 mg dose for chronic migraine patients. Peter McAllister, MD, from the New England Center for Neurology and Headache, noted that the FDA’s endorsement offers a new, convenient daily treatment for chronic migraine patients. The demonstrated efficacy and functional improvement of atogepant make it an appealing option for neurologists and headache specialists when devising treatment plans for patients. The […]